Ontology highlight
ABSTRACT:
SUBMITTER: Ohgino K
PROVIDER: S-EPMC7541018 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Ohgino Keiko K Terai Hideki H Yasuda Hiroyuki H Nukaga Shigenari S Hamamoto Junko J Tani Tetsuo T Kuroda Aoi A Arai Daisuke D Ishioka Kota K Masuzawa Keita K Ikemura Shinnosuke S Kawada Ichiro I Naoki Katsuhiko K Fukunaga Koichi K Soejima Kenzo K
Cancer science 20200805 10
ABT-263 (Navitoclax) is a BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, thereby inducing apoptosis. In small-cell lung cancer (SCLC) cells, the response to ABT-263 is associated with the expression of myeloid cell leukemia-1 (MCL-1) protein, however the efficacy of ABT-263 in non-small-cell lung cancer (NSCLC) has not been thoroughly evaluated. There are currently no established biomarkers for predicting the efficacy of ...[more]